Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_assertion type Assertion NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_head.
- NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_assertion description "[In this regard, besides a strong association between the HLA-DRB1?04 shared epitope alleles and both endothelial dysfunction, an early step in the atherosclerotic process, and clinically evident CV disease, other polymorphisms belonging to genes implicated in inflammatory and metabolic pathways, located inside and outside the HLA region, such as the 308 variant (G > A, rs1800629) of the TNFA locus, the rs1801131 polymorphism (A > C; position + 1298) of the MTHFR locus, or a deletion of 32 base pairs on the CCR5 gene, seem to be associated with the risk of CV disease in patients with RA.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_provenance.
- NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_assertion evidence source_evidence_literature NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_provenance.
- NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_assertion SIO_000772 22927710 NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_provenance.
- NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_assertion wasDerivedFrom befree-2016 NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_provenance.
- NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_assertion wasGeneratedBy ECO_0000203 NP1008558.RA2Y1xdQ5o8oxsf1zLCHoVn3hnWQWoWRu60ZbG3vBjJJg130_provenance.